Pharm/Biotech
Resources

Outsourcing Guide

Cont. Education

Software/Reports

Training Courses

Web Seminars

Jobs

Buyer's Guide

Home Page

Pharm Patents /
Licensing

Pharm News

Federal Register

Pharm Stocks

FDA Links

FDA Warning Letters

FDA Doc/cGMP

Pharm/Biotech Events

Consultants

Advertiser Info

Newsletter Subscription

Web Links

Suggestions

Site Map
 

 

 

 


Title:  Compositions containing polysaccharides from phellinus linteus and methods for treating diabetes mellitus using same

United States Patent:  6,809,084

Issued:  October 26, 2004

Inventors:  Kim; Hwanmook (Taejon, KR); Han; Sangbae (Cheongju-si, KR); Lee; Changwoo (Taejon, KR); Lee; Kihoon (Taejon, KR); Hong; Dongho (Taejon, KR)

Assignee:  Korea Research Institute of Bioscience and Biotechnology (Taejon, KR)

Appl. No.:  149117

Filed:  June 7, 2002

PCT Filed:  August 10, 2000

PCT NO:  PCT/KR00/00879

PCT PUB.NO.:  WO01/60385

PCT PUB. Date:  August 23, 2001

Abstract

The present invention relates to a novel use of polysaccharides (PL) from Phellinus linteus for treating diabetes mellitus, which provides medicine or food comprising polysaccharide as active components.

Description of the Invention

TECHNICAL FIELD

The present invention relates to a novel polysaccharide as an active component from Phellinus linteus for treating diabetes mellitus.

BACKGROUND ART

Diabetes mellitus and its complications are diseases with a high fatality rate in the world, together with cancer and cardiovascular diseases. According to a report issued by the National Commission on Diabetes, the fatality rate of diabetes is still continuously increasing. Diabetic patients, compared to normal persons, are highly susceptible to suffer from such complications as blindness, kidney disease and heart disease. Now, by the insulin therapy the acute or fatal symptoms of diabetes can be controlled, but the long-term complications reduce life expectancy.

Diabetes mellitus is classified into insulin-dependent diabetes mellitus (Type 1) and non-insulin-dependent diabetes mellitus (Type 2). Insulin-dependent diabetes mellitus is caused by damage of insulin-producing pancreatic beta cells, which leads to decrease of the amount of insulin and finally results in hyperglycemia.

Most insulin-dependent diabetes mellitus is the consequence of progressive beta-cell destruction during an asymptomatic period, often extending over many years. In the prediabetic period, circulating islet-cell autoantibodies and insulin autoantibodies may be detected. Insulin-dependent diabetes mellitus has been regarded as an autoimmune disease, and this hypothesis has been strengthened by the studies on the nonobese diabetic (NOD) mice and the BioBreeding (BB) rats. Both of these animals develop insulin-dependent diabetes mellitus spontaneously and their diabetic syndromes share many pathological features with that of humans with insulin-dependent diabetes mellitus. NOD mice, which can naturally fall into insulin-dependent diabetes mellitus, may usually start to expose the symptoms of diabetes in 12.about.14 weeks, and 80% of all mice have the symptoms. Immunocytes may be activated by unknown factors, and permeate into pancreatic ducts. In the islet, the immunocytes destroy beta cells and then bring about diabetes. Insulin acts on muscle, liver or fat cells to promote glucose metabolism and to lessen the level of glucose in blood. The diminution of insulin in blood by destruction of beta cells leads to deactivation of glucose metabolism in muscle or liver cell, resulting in diabetes mellitus. It has been reported in many studies that beta cell antigen, macrophages, helper T cells, cytotoxic T cells (CTLs), and the like are concerned with the outbreak of diabetes mellitus, and that oxygen free radicals or cytokines from inmiunocytes are responsible for destruction of beta cells.

Polysaccharide (PL) is a substance isolated from Phellinus linteus. Extraction of PL has been already disclosed (Chem. Pharm. Bull., 43(12), 2105-2108, 1995). PL can be extracted by the methods such as hydrothermal extraction, ethanol extraction method, DEAE-cellulose chromatography, and gel-permeation chromatography. PL comprise of 13.2% proteins and 82.5% saccharides, wherein 6.8% of the saccharides is uronic acid. MW of PL is definitely 153 KD, determined by gel-permeation chromatography. It was confirmed from neutral glucose composition analysis that PL consists of 7.0% of Ala, 3.7% of Xyl, 21.1% of glucose, 24.1% of Gal and 44.2% of Man, and from gas chromatography that uronic acid is a glucuronic acid 10 kinds of amino acids have been found in PL and Asp and Glu are major constituents. Saccharide parts and complete structure of PL play an important role on physiological activity of PL, but its protein parts are less significant. It has been found out that PL is polymer comprising O-type linkage (Chem. Pharm. Bull., 44(5), 1093-1095, 1996) and that PL is an immunoregulator for immunological enhancement (Int. J. Immunopharmacol 18(5), 295-303, 1996). PL improves entirely immune response. It has been confirmed by cell experiment and animal test that PL enhances the immunological function of T cells, macrophages, NK cells and B cells. Immunological enhancement of PL is effective to suppression of cancer growth or metastasis (Immunopharmacol, 41, 157-164, 1999). PL controlled the growth and transference of animal's cancer cell, B16F10, and the growth of human solid cancer cell, NCI-H23.

Diabetes research has been directed toward prevention and cure of insulin-dependent diabetes mellitus. Studies on prevention of insulitis and treatment of diabetes has mainly utilized the experimental models of diseases in laboratory animals such as NOD mice, and most therapeutic strategies for treatment of diabetes mellitus are directed to suppression and regulation of autoimmune response in order to prevent beta-cell destruction. Autoimmune disease, insulin-dependent diabetes mellitus results from increasing abnormalities of cellular immunity.

Various immunotherapies for preventing destruction of pancreatic beta-cells have been attempted. Neonatal thymectomy is the method of suppressing the outbreak of diabetes mellitus in NOD mice by killing T lymphocytes. Also, it has been known that depletion of macrophages or T cells using antibodies to T cell-dependent antigens represses diabetes. Some reports discloses that diabetes mellitus can be prevented by controlling production and reaction of free radical, for example, NO released from immunocytes by antioxidants such as nicotinamide, vitamin E, probucol, MDL29311, and U78518F, as has been reported.

To date, researches on immunosuppressive therapy are continued. However, treatment of diabetes mellitus utilizing glucocorticoids and cyclophosphamide has proved to be largely unsuccessful. Although studies on the use of cyclosporin A, rapamycin, and FK506 in diabetes appear to be encouraging, generalized immunosuppression involves potential complications including infections and drug-induced kidney and liver damage. Furthermore, curing with long-term administration can occasionally induce cancer. Studies on immunosuppressive therapy for diabetes mellitus is progressing, and the suppression of diabetes of NOD mice using cytokines such as IL-4 and IL-10 has been reported. Also, such immuno-regulatory agents as OK-432, LZ-8, BCG, and CFA have been reported to control diabetes mellitus of NOD mice, but their mechanism has yet to be established.

The present inventors achieved this invention, proving that polysaccharides (PL) from Phellinus linteus prevent destruction of pancreatic beta-cells, resulting in prevention and cure of diabetes mellitus.

DISCLOSURE OF THE INVENTION

The present invention provides a novel use of polysaccharide (PL) as active components from Phellinus linteus for treating diabetes mellitus.

The purpose of this invention was achieved by demonstrating effects of PL on prevention and cure of diabetes mellitus by administering PL from Phellinus linteus to NOD mice; examining inhibition of production of cytokine and suppression of streptozotosin-induced diabetes; and confirming that the diabetes-suppressing effect of PL originates from its selective regulation of immune response like above mentioned manners.

The present invention consists of following steps:

the step of comparing the urine glucose level of PL-injected NOD mice with that of control group, not receiving PL, in order to verify the diabetes-suppressive effect of PL from Phellinus linteus;

the step of observing the transition of pancreatitis to insulitis in PL-injected NOD mice, comparing to the case of control group, to verify the insulitis-suppressive effect of PL;

the step of measuring the expression level of cytokine MRNA in the separated spleen of NOD mice after a two-day intraperitoneal injection of the inventive PL, to confirm the diabetes-suppressive activity of PL based on its regulation of the cytokine production;

the step of transplanting lienal cells of non-PL-injected mice to NOD.Scid mice and measuring the occuring level of diabetes, to confirm that the inventive PL regulates immune responses and suppresses the outbreak of diabetes;

the step of checking it by analyzing difference between the blood glucose level of ICR mice with and without intraperitoneal injection of streptozotocin that PL cannot inhibit the beta cell destruction by streptozotocin, to confirm that the inventive PL has selective regulation of immune, responses resulting in suppression of diabetes mellitus; and

the step of examining their weight and mortality to investigate the side effects of PL on NOD mice.

Doses of the inventive PL were 100 mg/kg/day every other day with intraperitoneal injection. The dose level, route, and schedule of administration, however may vary depending on the condition of the subject.

PL suppressed completely crisis of diabetes mellitus of NOD mice. Prevention and cure of diabetes mellitus by PL was examined by the test, in which the urine or blood glucose level had been compared to that of control and significant drop was observed. PL inhibited lymphocyte infiltration into pancreatic ducts, to suppress insulitis.

Activation of T lymphocytes and macrophages plays an important role in autoimmune disease system. IL-2 and IFN-gamma, which are cytokine from Th1 cells, enhance autoimmune responses. IL-2 promotes destruction of beta cells by activating cytotoxic T cells (CTLs). IFN-gamma can activate macrophages, and the activated macrophages amplify the antigen presenting function to increase autoimmune responses. Simultaneously, free radicals such as activated oxygen may be increased, resulting in destruction of beta cells. Increase of IL-10 or IL-4 cytokine expression by cytokines from Th2 leads to inhibition of function of Th1 cell and consequently decline in autoimmune responses. IL-6 and IL12 are cytokines expressed by macrophages. Particularly, IL-12, which stimulates Th1 cells to enhance the production of IL-2, performs an important function in inducing autoimmune diseases such as diabetes mellitus. PL inhibited expression of such cytokines as IL-2, IFN-gamma, IL-10, IL-6 or IL-12, which play an important part in the occurrence of diabetes mellitus. Although the increment of secretion of IL-4 from Th2 is thought to have been a significant reason of the decline of Th1 cell function, nothing is supposed to do with decrease in the expression of IL-10. PL's regulating function works as a major factor of suppressing diabetes mellitus.

The important feature of this invention is that PL has a curing effect on diabetes mellitus without any negative effect. Since NOD mice receiving PL showed no drop of their weight and were never led to death, PL is expected to have no side effect.

Insulin-dependent diabetes mellitus can be induced by streptozotocin. Streptozotocin destroys selectively pancreatic beta cells, and diabetes mellitus induced by streptozotocin is similar with diabetes naturally occurring in NOD mice. NOD mice mediate the autoimmune responses to break the beta cells, whereas streptozotocin does not do that. PL could not suppress the destruction of beta cells occurring by streptozotocin. This result shows PL is a substance which regulates selectively the immune responses to suppress the outbreak of diabetes mellitus.

NOD mice are the best disease animal models in studies on insulin-dependent diabetes. NOD mice can naturally fall into insulin-dependent diabetes mellitus and the symptoms are very similar with those of human.

Claim 1 of 7 Claims

What is claimed is:

1. A composition comprising a polysaccharide substance (PL) as an active component from Phellinus linteus for treating diabetes mellitus, wherein the polysaccharide substance has the following features:

(a) said polysaccharide substance comprises 13.2% proteins and 82.5% saccharides, wherein 6.8% of the saccharides are uronic acid with Glc bound;

(b) molecular weight of PL is 153 KD; and

(c) the neutral sugar composition of the PL consists of 7.0% Ara, 3.7% Xyl, 21.1% Glc, 24.1% Gal, and 44.2% Man.




____________________________________________
If you want to learn more about this patent, please go directly to the U.S. Patent and Trademark Office Web site to access the full patent.

 

 

[ Outsourcing Guide ] [ Cont. Education ] [ Software/Reports ] [ Training Courses ]
[ Web Seminars ] [ Jobs ] [ Consultants ] [ Buyer's Guide ] [ Advertiser Info ]

[ Home ] [ Pharm Patents / Licensing ] [ Pharm News ] [ Federal Register ]
[ Pharm Stocks ] [ FDA Links ] [ FDA Warning Letters ] [ FDA Doc/cGMP ]
[ Pharm/Biotech Events ] [ Newsletter Subscription ] [ Web Links ] [ Suggestions ]
[ Site Map ]